| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
International uniform response criteria for multiple myeloma.
|
Leukemia
|
2006
|
17.78
|
|
2
|
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.
|
Leukemia
|
2008
|
3.41
|
|
3
|
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
|
Leukemia
|
2007
|
2.76
|
|
4
|
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.
|
Leukemia
|
2009
|
2.25
|
|
5
|
Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d'Etudes de la Greffe de Moelle Osseuse.
|
Blood
|
1992
|
2.11
|
|
6
|
Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation.
|
Leukemia
|
2003
|
1.96
|
|
7
|
Bone marrow mesenchymal stem cells are abnormal in multiple myeloma.
|
Leukemia
|
2007
|
1.86
|
|
8
|
Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle.
|
J Clin Oncol
|
2000
|
1.73
|
|
9
|
Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone.
|
Leukemia
|
2010
|
1.59
|
|
10
|
Leuconostoc, a potential pathogen in bone marrow transplantation.
|
Lancet
|
1993
|
1.54
|
|
11
|
Evaluation of a new low-dose digital x-ray device: first dosimetric and clinical results in children.
|
Pediatr Radiol
|
1998
|
1.52
|
|
12
|
Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials.
|
Leukemia
|
2007
|
1.48
|
|
13
|
Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy.
|
Eur J Immunol
|
1993
|
1.47
|
|
14
|
Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Société Française de Greffe de Moelle (SFGM).
|
Bone Marrow Transplant
|
2000
|
1.44
|
|
15
|
Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project.
|
Leukemia
|
2012
|
1.43
|
|
16
|
The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia.
|
Leukemia
|
2009
|
1.38
|
|
17
|
Hemolytic-uremic syndrome in a patient with chronic myelogenous leukemia treated with interferon alpha.
|
Am J Hematol
|
1994
|
1.38
|
|
18
|
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).
|
Leukemia
|
2009
|
1.38
|
|
19
|
Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM).
|
Blood
|
1995
|
1.36
|
|
20
|
Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte.
|
Ann Oncol
|
2000
|
1.34
|
|
21
|
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation.
|
Leukemia
|
2009
|
1.29
|
|
22
|
Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Société Française de Greffe de Moelle.
|
Blood
|
1996
|
1.23
|
|
23
|
Prognostic utility of intact immunoglobulin Ig'κ/Ig'λ ratios in multiple myeloma patients.
|
Leukemia
|
2012
|
1.23
|
|
24
|
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement.
|
Leukemia
|
2011
|
1.17
|
|
25
|
In vitro and in vivo enhancement of ricin-A chain immunotoxin activity by novel indolizine calcium channel blockers: delayed intracellular degradation linked to lipidosis induction.
|
Cancer Res
|
1992
|
1.17
|
|
26
|
Autologous haematopoietic stem cell transplants for autoimmune disease--feasibility and transplant-related mortality. Autoimmune Disease and Lymphoma Working Parties of the European Group for Blood and Marrow Transplantation, the European League Against Rheumatism and the International Stem Cell Project for Autoimmune Disease.
|
Bone Marrow Transplant
|
1999
|
1.17
|
|
27
|
The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT.
|
Bone Marrow Transplant
|
2013
|
1.14
|
|
28
|
Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Société Française de Greffe de moelle (SFGM).
|
Br J Haematol
|
2000
|
1.13
|
|
29
|
Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients.
|
Br J Haematol
|
1998
|
1.12
|
|
30
|
Second early allogeneic stem cell transplantations for graft failure in acute leukaemia, chronic myeloid leukaemia and aplastic anaemia. French Society of Bone Marrow Transplantation.
|
Br J Haematol
|
2000
|
1.12
|
|
31
|
Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease.
|
Blood
|
1998
|
1.06
|
|
32
|
Automated extraction and quantification of human cytomegalovirus DNA in whole blood by real-time PCR assay.
|
J Clin Microbiol
|
2003
|
1.05
|
|
33
|
Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia.
|
J Clin Oncol
|
1994
|
1.05
|
|
34
|
Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma.
|
Leukemia
|
2013
|
0.99
|
|
35
|
Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission.
|
Eur Cytokine Netw
|
2000
|
0.95
|
|
36
|
Abrogation of post-myeloablative chemotherapy neutropenia by ex-vivo expanded autologous CD34-positive cells.
|
Lancet
|
1999
|
0.95
|
|
37
|
In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma.
|
Eur J Immunol
|
1991
|
0.95
|
|
38
|
Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Société Francaise de Greffe de Moelle.
|
J Clin Oncol
|
1999
|
0.92
|
|
39
|
Familial multiple myeloma: report of fifteen families.
|
Br J Haematol
|
1999
|
0.90
|
|
40
|
Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial.
|
Blood
|
1999
|
0.90
|
|
41
|
The CD24 antigen discriminates between pre-B and B cells in human bone marrow.
|
J Immunol
|
1990
|
0.89
|
|
42
|
Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study.
|
Leukemia
|
1996
|
0.89
|
|
43
|
Antineutrophil cytoplasmic antibodies (ANCA) in chronic graft-versus-host disease after allogeneic bone marrow transplantation.
|
Bone Marrow Transplant
|
1997
|
0.88
|
|
44
|
Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and posttransplantation factors on outcome.
|
J Clin Oncol
|
2001
|
0.88
|
|
45
|
Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion.
|
Cancer Chemother Pharmacol
|
1993
|
0.88
|
|
46
|
Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT).
|
Ann Oncol
|
2011
|
0.87
|
|
47
|
Kaposi's sarcoma-associated herpesvirus infection and multiple myeloma.
|
Science
|
1997
|
0.86
|
|
48
|
Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen for patients receiving HLA-identical marrow grafts for acute myeloblastic leukemia in first complete remission.
|
Blood
|
2001
|
0.86
|
|
49
|
Oligonucleotide clonospecific probes directed against the junctional sequence of t(14;18): a new tool for the assessment of minimal residual disease in follicular lymphomas.
|
Br J Haematol
|
1996
|
0.86
|
|
50
|
Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-01 trial.
|
Leukemia
|
2010
|
0.86
|
|
51
|
A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.
|
Leukemia
|
1996
|
0.85
|
|
52
|
Enhanced activation of B cells in a granulocyte colony-stimulating factor-mobilized peripheral blood stem cell graft.
|
Br J Haematol
|
2001
|
0.84
|
|
53
|
Bone remodelling in monoclonal gammopathies of uncertain significance, symptomatic and nonsymptomatic myeloma.
|
Clin Rheumatol
|
1996
|
0.84
|
|
54
|
Hairy cell transformation of a B-cell chronic lymphocytic leukemia: a morphological, cytochemical, phenotypic and molecular study.
|
Leukemia
|
1991
|
0.84
|
|
55
|
Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French Registry on autologous transplantation in multiple myeloma.
|
Blood
|
1995
|
0.84
|
|
56
|
Evidence for a great medieval earthquake (~1100 A.D.) in the central Himalayas, Nepal.
|
Science
|
2005
|
0.83
|
|
57
|
bcl-2 proto-oncogene and Epstein-Barr virus latent membrane protein-1 expression in AIDS-related lymphoma.
|
Histopathology
|
1994
|
0.83
|
|
58
|
Comparison of MRI and computed tomography in the various stages of plasma cell disorders: correlations with biological and histological findings. Myélome-Midi-Pyrénées Group.
|
Clin Exp Rheumatol
|
1996
|
0.83
|
|
59
|
Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC).
|
Bone Marrow Transplant
|
2005
|
0.82
|
|
60
|
Allogeneic bone marrow transplantation for adult acute lymphoblastic leukemia in first complete remission: factors predictive of transplant-related mortality and influence of total body irradiation modalities.
|
Bone Marrow Transplant
|
1993
|
0.82
|
|
61
|
Increased vascularization in myeloma.
|
Eur J Haematol
|
2001
|
0.82
|
|
62
|
A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia.
|
Leuk Lymphoma
|
1998
|
0.81
|
|
63
|
The role of in vivo T-cell depletion on reduced-intensity conditioning allogeneic stem cell transplantation from HLA-identical siblings in patients with follicular lymphoma.
|
Leukemia
|
2010
|
0.80
|
|
64
|
Thalidomide in patients with advanced multiple myeloma.
|
Hematol J
|
2000
|
0.80
|
|
65
|
Nucleophosmin status may influence the therapeutic decision in de novo acute myeloid leukemia with normal karyotype.
|
Leukemia
|
2006
|
0.80
|
|
66
|
Rectal malacoplakia in renal transplantation: MR features.
|
J Comput Assist Tomogr
|
1994
|
0.79
|
|
67
|
The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission.
|
Leuk Lymphoma
|
1997
|
0.78
|
|
68
|
Lack of efficacy of clarithromycin in advanced multiple myeloma. Intergroupe Français du Myélome (IFM)
|
Leukemia
|
1999
|
0.78
|
|
69
|
High-dose therapy followed by stem cell transplantation in partial response after first-line induction therapy for aggressive non-Hodgkin's lymphoma.
|
Ann Oncol
|
1998
|
0.78
|
|
70
|
The role of autologous hematopoietic stem cell transplantation in multiple myeloma.
|
Semin Hematol
|
1997
|
0.78
|
|
71
|
Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas.
|
Cancer Res
|
1993
|
0.78
|
|
72
|
A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma.
|
Ann Oncol
|
2012
|
0.78
|
|
73
|
Myeloperoxidase: an enzyme involved in intrinsic vincristine resistance in human myeloblastic leukemia.
|
Blood
|
1993
|
0.77
|
|
74
|
Epstein-Barr virus in familial Hodgkin's disease.
|
Br J Haematol
|
1994
|
0.77
|
|
75
|
Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myeloma.
|
J Clin Oncol
|
1997
|
0.77
|
|
76
|
Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma.
|
Bone Marrow Transplant
|
1995
|
0.77
|
|
77
|
Risk factors for cytomegalovirus infection in BMT recipients transfused exclusively with seronegative blood products.
|
Bone Marrow Transplant
|
1993
|
0.76
|
|
78
|
Prevention of acute graft-versus-host disease by monoclonal antibody to interleukin-2 receptor.
|
Lancet
|
1989
|
0.76
|
|
79
|
Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation.
|
Blood
|
1990
|
0.76
|
|
80
|
Kaposi's sarcoma-associated herpesvirus (KSHV) in bone marrow biopsy from patients with multiple myeloma: PCR amplification of orf26 but not orf72 and orf75 sequences.
|
Br J Haematol
|
2000
|
0.76
|
|
81
|
Prevention of acute GVHD by in vivo use of anti-interleukin-2 receptor monoclonal antibody (33B3.1): a feasibility trial in 15 patients.
|
Bone Marrow Transplant
|
1991
|
0.76
|
|
82
|
New developments in conditioning regimens before auto-SCT in multiple myeloma.
|
Bone Marrow Transplant
|
2011
|
0.76
|
|
83
|
Effect of melphalan against self-renewal capacity of leukemic progenitors in acute myeloblastic leukemia.
|
Leukemia
|
1992
|
0.75
|
|
84
|
Hepatic veno-occlusive disease following bone marrow transplantation treated by prostaglandin E1.
|
Bone Marrow Transplant
|
1991
|
0.75
|
|
85
|
[Association of idiopathic lymphedema and familial acute leukemia. Apropos of a new case].
|
Presse Med
|
1985
|
0.75
|
|
86
|
Prospective randomized study of GVHD prevention using an anti IL2 receptor (CD25) MoAb after allogeneic bone marrow transplantation (BMT).
|
Bone Marrow Transplant
|
1991
|
0.75
|
|
87
|
Is there a place for blood stem-cell transplantation for the younger adult patient with acute myelogenous leukemia? BGMT Group.
|
J Clin Oncol
|
1994
|
0.75
|
|
88
|
[Neonatal herpetic laryngitis. Value of early diagnosis].
|
Presse Med
|
1988
|
0.75
|
|
89
|
Symptomatic osteonecrosis in recipients of nonautologous bone marrow transplants.
|
Rev Rhum Engl Ed
|
1995
|
0.75
|
|
90
|
Posterior reversible encephalopathy syndrome: two cases in young adults with acute lymphoblastic leukemia.
|
Leuk Res
|
2008
|
0.75
|
|
91
|
Dual-energy X-ray absorptiometry in patients with multiple myeloma and benign gammopathies.
|
Clin Exp Rheumatol
|
1996
|
0.75
|
|
92
|
Is allogeneic bone marrow transplantation the best treatment for young adult patients with acute myeloid leukemia in first complete remission. The BGMT Group.
|
Leukemia
|
1992
|
0.75
|
|
93
|
[Detection of residual disease in follicular lymphomas using the PCR technique: importance of clono-specific probes].
|
Bull Cancer
|
1998
|
0.75
|
|
94
|
t(14;14)(q11;q32) in biphenotypic blastic phase of chronic myeloid leukemia.
|
Blood
|
1986
|
0.75
|
|
95
|
Flow cytometric characterization of proliferating natural killer lymphocytes from bone marrow donors in the mixed lymphocyte reaction.
|
Cytometry
|
1998
|
0.75
|
|
96
|
Kaposi's sarcoma-associated herpesvirus (KSHV) in bone marrow biopsies of patients with Waldenstrom's macroglobulinaemia.
|
Br J Haematol
|
1998
|
0.75
|
|
97
|
Intravenous interleukin-2 just after high dose BCNU and autologous bone marrow transplantation. Report of a multicentric French pilot study.
|
Bone Marrow Transplant
|
1991
|
0.75
|
|
98
|
Autologous BMT for post-remission therapy in adult ALL: an immunological approach. For The French Group of Therapy of Adult ALL.
|
Leuk Lymphoma
|
1994
|
0.75
|
|
99
|
Vincristine degradation by serum from leukemic patients: role of myeloperoxidase.
|
Leuk Lymphoma
|
1996
|
0.75
|
|
100
|
Use of recombinant IL-2 (RU49637) after autologous bone marrow transplantation (BMT) in patients with hematological neoplasias: a phase 1 study.
|
Bone Marrow Transplant
|
1991
|
0.75
|
|
101
|
Immunohistochemical detection of multidrug resistance associated P-glycoprotein in stromal cells of malignant lymphomas.
|
Nouv Rev Fr Hematol
|
1990
|
0.75
|
|
102
|
Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in refractory lymphoma patients undergoing autologous bone marrow transplantation.
|
Semin Hematol
|
1994
|
0.75
|
|
103
|
Potential strategies for circumventing myeloperoxidase-catalyzed degradation of vinca alkaloids.
|
Leukemia
|
1994
|
0.75
|
|
104
|
Intensified conditioning regimen with busulfan followed by allogeneic BMT in children with myelodysplastic syndromes.
|
Bone Marrow Transplant
|
1994
|
0.75
|
|
105
|
A pilot study of autologous bone marrow transplantation followed by recombinant interleukin-2 in malignant lymphomas.
|
Leuk Lymphoma
|
1996
|
0.75
|
|
106
|
Immunotherapy by non-myeloablative allogeneic stem cell transplantation in multiple myeloma: results of a pilot study as salvage therapy after autologous transplantation.
|
Leukemia
|
2001
|
0.75
|
|
107
|
Association of the Philadelphia chromosome and 5q- in secondary blood disorder.
|
Cancer Genet Cytogenet
|
1988
|
0.75
|
|
108
|
[Veno-occlusive disease of the liver after bone marrow transplantation. Report of the symposium Autograft in France and the group of study of bone marrow transplantation. France Auto-Greffe et le Groupe d'Etude de la Greffe de Moelle osseuse].
|
Presse Med
|
1995
|
0.75
|
|
109
|
Association between intra-abdominal fat and hypertension in android obese diabetics.
|
Ann Med Interne (Paris)
|
1996
|
0.75
|
|
110
|
Early allogeneic transplantation favorably influences the outcome of adult patients suffering from acute myeloid leukemia. Société Française de Greffe de Moelle (SFGM).
|
Bone Marrow Transplant
|
1997
|
0.75
|
|
111
|
Recombinant interleukin-2 (rIL-2) after autologous bone marrow transplantation (BMT): a pilot study in 19 patients.
|
Eur Cytokine Netw
|
1992
|
0.75
|
|
112
|
[Initial antibacterial prophylaxis after bone marrow allograft. Pilot study with systemic vancomycin].
|
Pathol Biol (Paris)
|
1988
|
0.75
|
|
113
|
[Moschcowitz syndrome associated with Waldenström's disease].
|
Presse Med
|
1990
|
0.75
|
|
114
|
B-cell lymphoma following polycythemia vera: evidence for the involvement of two different clones.
|
Leukemia
|
1994
|
0.75
|
|
115
|
Do new therapeutic approaches (autotransplants, thalidomide, dexamethasone) improve the survival of patients with multiple myeloma followed in a rheumatology department?
|
Clin Rheumatol
|
2005
|
0.75
|
|
116
|
Bone marrow transplantation for myelodysplastic syndrome and secondary leukemia: outcome of 86 patients.
|
Bone Marrow Transplant
|
1991
|
0.75
|
|
117
|
Outcome of adult patients with acute myeloid leukemia who failed to achieve complete remission after one course of induction chemotherapy: a report from the BGMT Study Group.
|
Leuk Lymphoma
|
2001
|
0.75
|
|
118
|
Does more intensive treatment cure more patients with acute myeloid leukemia? The BGMT Group.
|
Semin Hematol
|
1991
|
0.75
|
|
119
|
Autologous stem cell transplantation after first remission induction treatment in multiple myeloma. A report of the French Registry on Autologous Transplantation in Multiple Myeloma.
|
Stem Cells
|
1995
|
0.75
|
|
120
|
Antisense inhibition of myeloperoxidase increases the sensitivity of the HL-60 cell line to vincristine.
|
Leukemia
|
1994
|
0.75
|
|
121
|
Trisomy 11 in acute myeloid leukemia: ten cases.
|
Leukemia
|
1994
|
0.75
|
|
122
|
Second primary malignancies in multiple myeloma: an overview and IMWG consensus.
|
Ann Oncol
|
2017
|
0.75
|
|
123
|
[Magnetic resonance imaging in the bone sites of malignant non-Hodgkin's lymphoma. Apropos of 16 cases].
|
Ann Radiol (Paris)
|
1991
|
0.75
|
|
124
|
Allogeneic versus autologous bone marrow transplantation versus chemotherapy for treatment of acute myeloid leukemia in first complete remission (BGM 84 and BGMT 87 studies). The BGMT Group.
|
Bone Marrow Transplant
|
1991
|
0.75
|
|
125
|
Autologous stem cell transplantation versus chemotherapy for adult patients with acute myeloid leukemia in first remission: the BGMT Group experience.
|
Nouv Rev Fr Hematol
|
1993
|
0.75
|